Trial · NCT00759525

The Role of Mineralocorticoid Receptors in Vascular Function

NCT00759525, Phase 2, Phase 3, Completed, Brigham and Women's Hospital; results first posted 2015-05-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. The Role of Mineralocorticoid Receptors in Vascular Function. Trials, record NCT00759525. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00759525

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Role of Mineralocorticoid Receptors in Vascular Function
NCT number: NCT00759525
Status: Completed
Phases: Phase 2, Phase 3
Enrollment: 15 participants, actual
Lead sponsor: Brigham and Women's Hospital
Conditions: Apparent Mineralocorticoid Excess (AME)
Interventions: Glycyrrhetic Acid, Placebo
First posted: 2008-09-25
Last updated: 2016-10-26
Results first posted: 2015-05-28

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Forearm Blood Flow	Outcome was measured at the end of each study period (i.e. 14 days after Baseline measurements were taken)	At the end of each 14-day intervention (Glycyrrhinitic acid or Placebo), vascular endothelial function was assessed by measuring forearm blood flow and comparing to Baseline. The outcome measure depicted below reflects the change in forearm blood flow from Baseline after completing the glycyrrhinitic acid regimen as well as the change in forearm blood flow from Baseline after taking the matching placebo.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Forearm Blood Flow	Outcome was measured at the end of each study period (i.e. 14 days after Baseline measurements were taken)		ml/100ml of tissue/min	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Forearm Blood Flow	Glycyrrhinitic Acid		1.87	Standard Error 0.26	ml/100ml of tissue/min
Forearm Blood Flow	Placebo		1.34	Standard Error 0.20	ml/100ml of tissue/min

Source ClinicalTrials.gov

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Intervention (14 Days)	STARTED	Glycyrrhetinic Acid First, Then Placebo	7
First Intervention (14 Days)	STARTED	Placebo First, Then Glycyrrhetinic Acid	8
First Intervention (14 Days)	COMPLETED	Glycyrrhetinic Acid First, Then Placebo	7
First Intervention (14 Days)	COMPLETED	Placebo First, Then Glycyrrhetinic Acid	8
First Intervention (14 Days)	NOT COMPLETED	Glycyrrhetinic Acid First, Then Placebo	0
First Intervention (14 Days)	NOT COMPLETED	Placebo First, Then Glycyrrhetinic Acid	0
Washout (14 Days)	STARTED	Glycyrrhetinic Acid First, Then Placebo	7
Washout (14 Days)	STARTED	Placebo First, Then Glycyrrhetinic Acid	8
Washout (14 Days)	COMPLETED	Glycyrrhetinic Acid First, Then Placebo	7
Washout (14 Days)	COMPLETED	Placebo First, Then Glycyrrhetinic Acid	8

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Glycyrrhetinic Acid First, Then Placebo
Total, all-cause mortality	Placebo First, Then Glycyrrhetinic Acid
Total, other adverse events	Glycyrrhetinic Acid First, Then Placebo	0	7
Total, other adverse events	Placebo First, Then Glycyrrhetinic Acid	0	8
Total, serious adverse events	Glycyrrhetinic Acid First, Then Placebo	0	7
Total, serious adverse events	Placebo First, Then Glycyrrhetinic Acid	0	8

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
20515440	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Glycyrrhetinic Acid First, Then Placebo vs Placebo First, Then Glycyrrhetinic Acid: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00759525

GET https://conductscience.org/api/trials/v1/NCT00759525/registered

API reference For AI assistants